Predklinička ispitivanja inhibicijskog i interakcijskog potencijala novih lijekova na razini citokroma P450

Stručni rad - Stručni rad

• Autor: Mirza Bojić
• Autorova ustanova: Sveučilište u Zagrebu; Farmaceutsko-biokemijski fakultet; (Zavod za farmaceutsku kemiju)
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Farmacija; Farmacija

Sažetak (engleski)

In 1998 mibefradil - an antihypertensive drug, blocker of calcium channel, was
withdrawn from the marked after more than 30 clinically significant interactions
with other xenobiotics were reported in less than a year on the market. As in most
cases enzyme involved was from the superfamily of cytochromes P4SO. In this paper
approach in studying cytochromes P450 and drug inhibitions in vitro is reviewed.
Different types of inhibition are described: direct and time dependent inhibition, and
metabolism dependent inactivation. These studies were accepted by pharmaceutical
industry for the assessment of potential drug-drug interactions in early stages of drug
development, and now are being formalized by regulatory bodies in Europe (2013),
Japan (2014) and USA to follow.

• Ključne riječi (hrvatski): citokrom P450; genetski polimorfizam; inhibicija enzima
• Jezik: hrvatski
• Vrsta publikacije: Stručni rad - Stručni rad
• Status objave: Objavljen
• Vrsta recenzije: Recenziran - domaća recenzija
• Verzija publikacije: Objavljena verzija rada (izdavačev PDF)
• Naslov časopisa: Farmaceutski glasnik
• Brojčani podaci: vol. 71, br. 5, str. 229-242
• p-ISSN: 0014-8202
• URN:NBN: urn:nbn:hr:163:107539
• Datum objave publikacije: 2015
• Vrsta resursa: Tekst
• Prava pristupa: Otvoreni pristup
• Datum i vrijeme pohrane: 2020-10-02 09:38:03